Status:

COMPLETED

Ulcerative Colitis Relapse Prevention Trial, Hypnosis

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

National Center for Complementary and Integrative Health (NCCIH)

Conditions:

Ulcerative Colitis

Inflammatory Bowel Disease

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

The UCRPT is a randomized controlled trial to determine if a type of hypnotherapy will maintain remission in patients affected by Ulcerative Colitis.

Detailed Description

The purpose of the study is to determine whether hypnotherapy can serve as an effective therapy for patients with Ulcerative Colitis (UC), a chronic, relapsing and remitting inflammatory bowel disease...

Eligibility Criteria

Inclusion

  • male and female patients between the ages of 18 and 70 of any ethnicity
  • endoscopy-confirmed (within the past 2 years) mild or moderately severe Ulcerative Colitis (at time of previous flare)
  • inactive disease at the time of recruitment:
  • Mayo score \<2 with no subscale \>1
  • no rectal bleeding
  • Physician Global Assessment Score (PGA) = 0
  • 2 weeks of baseline daily symptom diaries that support criteria for inactive disease
  • documented disease flare within the past 1.5 years to enhance the opportunity to observe differences between groups in a 1-year trial .
  • no medication or a stable dose of maintenance medication (i.e. mesalamine or sulfasalazine) for at least one month prior to enrollment.
  • If taking maintenance medication: an increase in dose will be considered a relapse
  • If taking no medication: initiation of any medication will be considered a relapse

Exclusion

  • active disease
  • daily rectal bleeding for past 7 days
  • Mayo Score \> 2, any subscale \> 1
  • PGA score \>0
  • history of severe or fulminant UC
  • most recent flare included \> 6 bloody stools a day
  • history of of toxicity including fever, tachycardia, anemia or an elevated Erythrocyte sedimentation rate (ESR) ∙ history of continuous bleeding, blood transfusion requirement, abdominal tenderness and distension, and colonic dilation on abdominal plain films
  • other gastrointestinal conditions
  • Crohn's Disease (CD)
  • short-bowel syndrome
  • celiac sprue
  • irritable bowel syndrome (IBS)
  • renal or hepatic disease
  • positive stool exam (bacteria, ova, parasites)
  • C-difficile
  • history of colon resection
  • steroid-dependent, patients taking oral steroids within the past 30 days, topical steroids within the past week, quit smoking in the past 30 days given the known effects of smoking cessation on UC disease flare 23.
  • contraindications for hypnotherapy
  • unresolved history of physical or sexual abuse
  • a current or past dissociative disorder (i.e. Borderline PD, PTSD)
  • history of psychosis (including mania)
  • history of psychiatric hospitalization, including for self-harm or SI/HI
  • current substance abuse
  • severe psychiatric disorder
  • patients who are resistant to hypnosis as a result of religious or moral beliefs or any other reason

Key Trial Info

Start Date :

July 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2012

Estimated Enrollment :

55 Patients enrolled

Trial Details

Trial ID

NCT00798642

Start Date

July 1 2007

End Date

June 1 2012

Last Update

April 2 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Northwestern University, Feinberg School of Medicine

Chicago, Illinois, United States, 60611